glp-1 weight loss drug news november 2025 Novo cuts prices 70%, but semaglutide revenue could grow in 2026 The GLP-1 Access Gap: Mapping

Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the effect of liraglutide on insulin-associated weight gain in patients with type 2 diabetes (ELEGANT) randomized controlled trial

However, developing an effective, safe, and tolerable oral small-molecule GLP-1 has proven incredibly challenging

de Athayde De Hollanda, A

Lose 14-15% of your body weight* *In clinical trials of Wegovy (FDA-approved semaglutide), participants achieved an average weight loss of approximately 15% over 68 weeks, with some participants achieving up to 20% with continued treatment and adherence, when combined with diet and exercise

Be sure to talk to your healthcare provider to figure out the best approach for your needs

Verify current pricing directly with Ro before making financial decisions